TapImmune Inc. — Form 10-Q Summary
Entity note: The filing provided is for TapImmune Inc., not Marker Therapeutics, Inc. It covers the quarter and nine months ended September 30, 2015. Financial statements are unaudited.
Business context and reporting period
TapImmune described itself as a clinical-stage immunotherapy company developing peptide- and gene-based cancer vaccines. Its main programs were folate receptor alpha (FRα) for breast and ovarian cancer and HER2/neu for breast cancer, with Polystart and TAP technologies in development.
Financial results and position
| Metric | Period / date | Amount |
|---|---|---|
| Revenue | Three and nine months ended September 30, 2015 | None reported |
| Operating expenses | Q3 2015 / Q3 2014 | $1.738 million / $1.384 million |
| Net income (loss) | Q3 2015 / Q3 2014 | $2.484 million / $(1.568) million |
| Net loss | Nine months 2015 / 2014 | $(16.943) million / $(30.147) million |
| Operating cash flow | Nine months 2015 / 2014 | $(3.492) million / $(1.518) million |
| Cash | September 30, 2015 | $6.087 million |
| Working capital | September 30, 2015 | $(2.621) million |
| Current liabilities | September 30, 2015 | $8.847 million |
Q3 2015 net income was driven by a $4.247 million gain from the change in fair value of warrant liabilities, not operating performance. For the first nine months, the company recorded a $4.759 million loss from fair-value changes and an $8.256 million warrant inducement expense. The filing reports no revenue; gross margin is therefore not applicable. The company had no material long-term debt shown; current obligations included $52,942 in promissory notes, $492,365 in research agreement obligations, and a $7.427 million warrant derivative liability.
Cash increased from $142,000 at December 31, 2014, mainly reflecting $9.438 million of financing proceeds, including $7.428 million from warrant exercises and approximately $2.010 million net from private placements. Common shares outstanding rose to 62.891 million at September 30, 2015 from 20.319 million at year-end 2014. The filing states 64,618,762 shares outstanding as of November 16, 2015.
Material changes versus the prior comparable period
- Operating expenses increased 26% in Q3 and 31% for the nine-month period, largely reflecting higher research and development costs, including a $350,000 Mayo license payment and increased research and consulting activity.
- General and administrative expenses declined year over year, primarily due to lower non-cash consulting and stock compensation costs.
- Q3 moved from a loss to reported income because of the warrant-liability fair-value gain. The nine-month net loss narrowed from 2014, which included a substantial debt-settlement loss.
- Financing materially improved cash, but the company remained in a working-capital deficit and issued substantial equity and warrants.
Outlook, risks, contingencies, and unusual items
- Management estimated spending of approximately $7.5 million over the next 12 months, including funding for multiple Phase II trials, and said additional financing was necessary. It expected warrant exercises to be a potential funding source but gave no assurance of success.
- The company stated that its resources were insufficient to support operations and that substantial doubt existed about its ability to continue as a going concern. It expected continued losses, and commercialization would require further development and regulatory approval.
- Management reported that a $13.3 million U.S. Department of Defense grant to Mayo Clinic collaborators would fund a 280-patient Phase II FRα trial in triple-negative breast cancer. TapImmune said it would provide clinical and manufacturing expertise and vaccine formulations.
- Management reported completed Phase I studies with positive immune responses in 20 of 21 evaluable FRα patients and 19 of 20 evaluable HER2/neu patients. These are management-reported clinical observations, not evidence of commercial efficacy. HER2/neu Phase II planning was described as targeting 2016.
- Warrant valuation relied on Level 3, unobservable inputs and could change materially. The filing says the cash settlement value could differ significantly from the recorded liability.
- Disclosure controls and procedures were determined to be ineffective as of period-end. The filing also disclosed a $51,000 vendor judgment intended for settlement and a separate consultant arbitration award of $196,204 plus interest that the company was attempting to collect.
- After quarter-end, the company disclosed additional warrant exercises for $864,000 through November 12, 2015, expanded its equity plan reserve, and approved significant executive and other equity awards.
- No formal earnings or revenue guidance was provided. The filing states there were no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the filing entity: this report identifies TapImmune Inc., whereas the request names Marker Therapeutics, Inc.
- Assess cash runway against the stated $7.5 million expected spending and the company’s disclosed need for additional capital.
- Review warrant terms, potential dilution, derivative-liability valuation assumptions, and subsequent warrant exercises.
- Verify the status, funding arrangements, and timeline of the Mayo Clinic Phase II program and the reported DoD grant.
- Review the company’s ineffective disclosure controls, going-concern warning, and disclosed legal matters.